Newsletter Tool

To view this email as a web page, click here

Today's Rundown

With Biovac agreement, Pfizer and BioNTech extend their COVID-19 vaccine manufacturing network to Africa
‘Light at the end of the COVID-19 tunnel’ as J&J’s medtech companies rebound to $7B in second-quarter sales
YouTube partners with Mass General on health content amid misinformation backlash
Catalent makes a $100M splash to add biologics drug substance firepower at Italian plant
Sanofi-GSK's COVID-19 vaccine enters EMA rolling review as the companies work on phase 3 trial
Johnson & Johnson eyes $2.5B in COVID vaccine sales as key immunology, oncology meds trounce expectations
Biotech earnings arrive under cloud of Delta variant, but Q2 gene editing results still offer reason to celebrate
UPDATED Coronavirus tracker: Banner Health unveils $10,000 prize drawings for fully vaccinated employees
AbbVie, Roche top data transparency list, but more could be done to build trust in medical system: report

Featured Story

With Biovac agreement, Pfizer and BioNTech extend their COVID-19 vaccine manufacturing network to Africa

By Kevin Dunleavy

Lifting patent protections on COVID-19 vaccines could eventually allow poor countries to produce shots. But Pfizer and BioNTech have a more ready solution: The companies have inked manufacturing agreement with Biovac of South Africa, which will allow the companies to supply vaccines to the continent by as soon as next year.

‘Light at the end of the COVID-19 tunnel’ as J&J’s medtech companies rebound to $7B in second-quarter sales

By Conor Hale

Johnson & Johnson’s medtech companies have rebounded in a big way during this year’s second quarter, outpacing prepandemic earnings in some treatment areas, as the wider market continues to recover from last year’s COVID-19 lockdowns.

YouTube partners with Mass General on health content amid misinformation backlash

By Heather Landi

The first thing many people do when they have a health question is head online. With a deluge of misinformation about COVID-19 and vaccines on the Internet, YouTube is taking steps to surface more credible health information.

Catalent makes a $100M splash to add biologics drug substance firepower at Italian plant

By Fraiser Kansteiner

Contract manufacturer Catalent's star has risen sharply over the last year thanks to a series of high-profile COVID-19 vaccine production pacts. Now, it's keeping the momentum going with plans to add biologics firepower at a key factory in the pandemic fight.

Sanofi-GSK's COVID-19 vaccine enters EMA rolling review as the companies work on phase 3 trial

By Kyle LaHucik

Sanofi and GlaxoSmithKline passed a small phase 2 COVID-19 vaccine test in mid-May and began enrollment for a global phase 3 later that month, with hopes for a fourth quarter approval. That process picked up steam Tuesday with the European Medicines Agency saying it started a rolling review of the potential vaccine.

Johnson & Johnson eyes $2.5B in COVID vaccine sales as key immunology, oncology meds trounce expectations

By Fraiser Kansteiner

Johnson & Johnson's COVID-19 vaccine delivered $164 million in sales for the second quarter. By year-end, the company expects the shot to gin up $2.5 billion. Meanwhile, the Big Pharma's drug, medical device and consumer health businesses all did gangbusters amid the pandemic recovery, J&J execs said on a Q2 earnings call.

Biotech earnings arrive under cloud of Delta variant, but Q2 gene editing results still offer reason to celebrate

By Annalee Armstrong

The Delta variant driving up COVID-19 infections in the U.S. will certainly cast a pall over earnings, but biotechs saw a boost in the second quarter with some new gene editing results that reinvigorated interest in companies developing the technology. But gene therapy had a moment in the sun, too—one that might have been too bright.

UPDATED Coronavirus tracker: Banner Health unveils $10,000 prize drawings for fully vaccinated employees

By Healthcare Staff

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

AbbVie, Roche top data transparency list, but more could be done to build trust in medical system: report